Advanced Biomed Inc. Common Stock (ADVB)

US — Healthcare Sector
Peers: BGLC  BNR  GBS  RADX  SSKN  LUCY  BCDA  PAVM  CELZ  DHAI 

Automate Your Wheel Strategy on ADVB

With Tiblio's Option Bot, you can configure your own wheel strategy including ADVB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ADVB
  • Rev/Share 0.0
  • Book/Share 0.0055
  • PB 79.9832
  • Debt/Equity 0.3637
  • CurrentRatio 2.088
  • ROIC -11.9899

 

  • MktCap 9521600.0
  • FreeCF/Share -0.0482
  • PFCF -9.1256
  • PE -3.6904
  • Debt/Assets 0.1942
  • DivYield 0
  • ROE -1.7311

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
ADVB
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The Shares began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol “ADVB.”

Read More
image for news Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering

About Advanced Biomed Inc. Common Stock (ADVB)

  • IPO Date 2025-03-06
  • Website https://www.advanbiomed.com
  • Industry Medical - Diagnostics & Research
  • CEO Yi Lu
  • Employees 40
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.